daunorubicin ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antineoplastics, daunorubicin derivatives 786 20830-81-3

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • daunorubicin
  • acetyladriamycin
  • cerubidin
  • daunoblastina
  • daunomycine
  • daunorubicine
  • Leukaemomycin C
  • rubidomycin
  • daunorubicin hydrochloride
  • daunorubicin citrate
  • daunorubicin HCl
A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of LEUKEMIA and other NEOPLASMS.
  • Molecular weight: 527.53
  • Formula: C27H29NO10
  • CLOGP: 0.78
  • LIPINSKI: 2
  • HAC: 11
  • HDO: 5
  • TPSA: 185.84
  • ALOGS: -2.93
  • ROTB: 4

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.04 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0.50 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 2.05 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
Vd (Volume of distribution) 32.05 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 47.57 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.06 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 14.24 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Dec. 19, 1979 FDA
Feb. 24, 2021 PMDA Meiji Seika Pharma Co., Ltd

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Febrile neutropenia 673.79 24.68 342 9416 97325 50498041
Hypofibrinogenaemia 364.80 24.68 75 9683 1037 50594329
Sepsis 161.43 24.68 161 9597 132764 50462602
Posterior reversible encephalopathy syndrome 159.70 24.68 71 9687 14857 50580509
Hyperbilirubinaemia 140.53 24.68 57 9701 9513 50585853
Neutropenia 126.57 24.68 149 9609 147816 50447550
Bone marrow failure 113.27 24.68 69 9689 27555 50567811
Mucormycosis 111.47 24.68 34 9724 2449 50592917
Pneumatosis intestinalis 108.24 24.68 32 9726 2071 50593295
Febrile bone marrow aplasia 104.51 24.68 41 9717 6270 50589096
Colitis 101.46 24.68 73 9685 38456 50556910
Second primary malignancy 94.07 24.68 39 9719 6875 50588491
Septic shock 93.82 24.68 82 9676 57093 50538273
Human bocavirus infection 92.49 24.68 20 9738 356 50595010
Clostridium difficile colitis 90.33 24.68 51 9707 17691 50577675
Haematotoxicity 89.08 24.68 39 9719 7856 50587510
Thrombocytopenia 85.76 24.68 114 9644 127559 50467807
Cardiotoxicity 83.49 24.68 36 9722 6991 50588375
Secondary immunodeficiency 83.27 24.68 23 9735 1165 50594201
Human herpesvirus 6 infection 81.11 24.68 27 9731 2579 50592787
Herpes simplex 79.58 24.68 35 9723 7127 50588239
Blood culture positive 74.90 24.68 29 9729 4279 50591087
Enterobacter infection 72.75 24.68 23 9735 1865 50593501
Bronchopulmonary aspergillosis 71.32 24.68 33 9725 7559 50587807
Aplasia 71.06 24.68 27 9731 3786 50591580
Neutropenic colitis 67.17 24.68 23 9735 2394 50592972
Venoocclusive disease 60.42 24.68 20 9738 1876 50593490
Ejection fraction decreased 60.28 24.68 40 9718 18480 50576886
Left atrial hypertrophy 59.46 24.68 10 9748 40 50595326
Cerebral venous sinus thrombosis 58.84 24.68 19 9739 1649 50593717
Mucosal inflammation 58.75 24.68 54 9704 40088 50555278
Fatigue 58.60 24.68 32 9726 707569 49887797
Disseminated intravascular coagulation 58.18 24.68 38 9720 17097 50578269
Arthralgia 58.03 24.68 8 9750 438694 50156672
Gastroenteritis norovirus 57.97 24.68 19 9739 1728 50593638
Multiple organ dysfunction syndrome 55.51 24.68 58 9700 50279 50545087
Bacterial infection 55.02 24.68 36 9722 16245 50579121
Pancytopenia 54.77 24.68 74 9684 83956 50511410
Haemophagocytic lymphohistiocytosis 52.73 24.68 28 9730 8605 50586761
Pneumonia fungal 50.88 24.68 22 9736 4298 50591068
Tumour lysis syndrome 50.86 24.68 26 9732 7395 50587971
Venous thrombosis 50.18 24.68 22 9736 4444 50590922
Aspergillus infection 49.97 24.68 25 9733 6796 50588570
Pain 49.61 24.68 25 9733 578878 50016488
Angiokeratoma 49.11 24.68 10 9748 131 50595235
Rhinovirus infection 48.29 24.68 20 9738 3514 50591852
Pyrexia 45.93 24.68 169 9589 380034 50215332
Acute myeloid leukaemia recurrent 45.65 24.68 15 9743 1375 50593991
Pneumonia moraxella 45.32 24.68 8 9750 45 50595321
Cerebral venous thrombosis 45.05 24.68 16 9742 1855 50593511
Hepatic failure 44.47 24.68 42 9716 32241 50563125
Electrocardiogram PR shortened 44.15 24.68 10 9748 222 50595144
Stenotrophomonas infection 42.96 24.68 15 9743 1654 50593712
Neutropenic sepsis 42.31 24.68 29 9729 14118 50581248
Pulse waveform abnormal 42.03 24.68 8 9750 72 50595294
Ankle brachial index decreased 41.93 24.68 8 9750 73 50595293
Bacteraemia 41.79 24.68 29 9729 14404 50580962
Carotid intima-media thickness increased 41.54 24.68 8 9750 77 50595289
Venoocclusive liver disease 41.52 24.68 19 9739 4242 50591124
Neoplasm recurrence 41.37 24.68 16 9742 2353 50593013
Enterococcal infection 41.08 24.68 22 9736 6876 50588490
Enteritis 40.79 24.68 22 9736 6973 50588393
Staphylococcal sepsis 40.67 24.68 22 9736 7014 50588352
Acute lymphocytic leukaemia recurrent 40.49 24.68 15 9743 1960 50593406
Respiratory failure 39.01 24.68 66 9692 91115 50504251
Blood bilirubin increased 37.26 24.68 38 9720 32000 50563366
Streptococcal bacteraemia 37.13 24.68 13 9745 1445 50593921
Bone marrow disorder 37.04 24.68 14 9744 1934 50593432
Alanine aminotransferase increased 36.53 24.68 63 9695 88296 50507070
Blast crisis in myelogenous leukaemia 36.28 24.68 10 9748 502 50594864
Otitis externa 36.27 24.68 13 9745 1547 50593819
Tachycardia 34.72 24.68 66 9692 99697 50495669
Neurotoxicity 34.42 24.68 26 9732 14714 50580652
Malaise 34.36 24.68 11 9747 335521 50259845
Chronic myeloid leukaemia recurrent 34.18 24.68 8 9750 206 50595160
Acute myeloid leukaemia 33.90 24.68 26 9732 15048 50580318
Minimal residual disease 32.84 24.68 7 9751 116 50595250
Aborted pregnancy 32.61 24.68 6 9752 44 50595322
Leukaemia recurrent 31.24 24.68 11 9747 1243 50594123
Pleural effusion 30.98 24.68 56 9702 81398 50513968
Fall 30.88 24.68 13 9745 334919 50260447
Hepatocellular injury 30.58 24.68 31 9727 25916 50569450
Differentiation syndrome 30.36 24.68 10 9748 923 50594443
Leukopenia 30.36 24.68 50 9708 67478 50527888
Left ventricular dysfunction 30.15 24.68 21 9737 10485 50584881
Genotoxicity 29.73 24.68 5 9753 20 50595346
Dysplasia 29.05 24.68 9 9749 682 50594684
Device related infection 28.60 24.68 27 9731 20708 50574658
Breakthrough pain 28.41 24.68 10 9748 1129 50594237
Leukoerythroblastosis 28.24 24.68 7 9751 231 50595135
Metastases to pancreas 28.21 24.68 7 9751 232 50595134
Respiratory distress 28.13 24.68 32 9726 30457 50564909
Dyspnoea 27.98 24.68 39 9719 547569 50047797
Geotrichum infection 27.94 24.68 8 9750 462 50594904
Trichosporon infection 27.90 24.68 7 9751 243 50595123
Cholestasis 27.50 24.68 29 9729 25372 50569994
Ileus paralytic 27.20 24.68 14 9744 4036 50591330
Ureaplasma infection 27.17 24.68 8 9750 510 50594856
Abdominal discomfort 26.70 24.68 6 9752 231635 50363731
Lung opacity 26.39 24.68 11 9747 1962 50593404
Nausea 26.39 24.68 61 9697 705337 49890029
Hypotension 26.12 24.68 102 9656 235367 50359999
Pseudomonas test positive 25.21 24.68 8 9750 656 50594710
Hyperglycaemia 25.13 24.68 33 9725 36372 50558994
Escherichia infection 24.88 24.68 19 9739 10922 50584444

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Febrile neutropenia 506.62 20.65 390 11322 111850 29450965
Hypofibrinogenaemia 327.82 20.65 83 11629 1418 29561397
Posterior reversible encephalopathy syndrome 191.85 20.65 86 11626 8890 29553925
Aspergillus infection 157.43 20.65 79 11633 10502 29552313
Neutropenia 155.88 20.65 224 11488 131487 29431328
Septic shock 143.76 20.65 149 11563 62411 29500404
Bone marrow failure 130.90 20.65 99 11613 27350 29535465
Sepsis 127.21 20.65 213 11499 142469 29420346
Multiple-drug resistance 122.04 20.65 49 11663 3851 29558964
Hyperbilirubinaemia 121.63 20.65 75 11637 14859 29547956
Haematotoxicity 120.62 20.65 57 11655 6642 29556173
Mucormycosis 112.03 20.65 50 11662 5108 29557707
Hypertriglyceridaemia 108.79 20.65 55 11657 7420 29555395
Bronchopulmonary aspergillosis 105.65 20.65 64 11648 12280 29550535
Acute myeloid leukaemia recurrent 98.54 20.65 34 11678 1746 29561069
Leukaemia recurrent 77.08 20.65 27 11685 1450 29561365
Pancytopenia 72.35 20.65 123 11589 83045 29479770
Neutropenic colitis 70.98 20.65 29 11683 2382 29560433
Colitis 70.88 20.65 74 11638 31174 29531641
Acute lymphocytic leukaemia recurrent 69.79 20.65 29 11683 2487 29560328
Multiple organ dysfunction syndrome 68.11 20.65 103 11609 63013 29499802
Hepatotoxicity 67.03 20.65 56 11656 17811 29545004
Pyrexia 64.46 20.65 254 11458 287368 29275447
Cerebral venous thrombosis 63.35 20.65 19 11693 619 29562196
Venoocclusive disease 62.87 20.65 27 11685 2512 29560303
Glioma 62.52 20.65 16 11696 285 29562530
Blood fibrinogen decreased 60.53 20.65 20 11692 898 29561917
Pneumonia fungal 60.09 20.65 34 11678 5743 29557072
Fungal infection 60.02 20.65 47 11665 13638 29549177
Osteonecrosis 58.36 20.65 46 11666 13473 29549342
Febrile bone marrow aplasia 57.50 20.65 36 11676 7315 29555500
Tumour lysis syndrome 57.28 20.65 46 11666 13838 29548977
Bacteraemia 56.79 20.65 49 11663 16274 29546541
Central nervous system fungal infection 55.80 20.65 15 11697 326 29562489
Myelosuppression 51.48 20.65 41 11671 12186 29550629
Glioblastoma multiforme 49.70 20.65 16 11696 661 29562154
Fatigue 47.43 20.65 34 11678 316787 29246028
Blood bilirubin increased 41.87 20.65 59 11653 33834 29528981
Death 41.23 20.65 45 11667 342039 29220776
Oesophageal stenosis 40.25 20.65 17 11695 1518 29561297
Cerebral venous sinus thrombosis 40.04 20.65 12 11700 390 29562425
Neoplasm recurrence 39.23 20.65 18 11694 1959 29560856
Mucosal inflammation 37.55 20.65 54 11658 31541 29531274
Large intestine infection 35.94 20.65 15 11697 1300 29561515
Lower respiratory tract infection fungal 35.73 20.65 12 11700 567 29562248
Candida infection 34.40 20.65 36 11676 15189 29547626
Congenital pneumonia 34.35 20.65 8 11704 94 29562721
Personality change due to a general medical condition 34.24 20.65 7 11705 42 29562773
Candida endophthalmitis 33.68 20.65 8 11704 103 29562712
Device related infection 33.60 20.65 36 11676 15600 29547215
Haemophagocytic lymphohistiocytosis 33.46 20.65 30 11682 10474 29552341
Respiratory failure 33.21 20.65 99 11613 97032 29465783
Acute monocytic leukaemia 33.10 20.65 10 11702 334 29562481
Disseminated intravascular coagulation 32.77 20.65 40 11672 19940 29542875
Intussusception 32.72 20.65 11 11701 521 29562294
Systemic mycosis 32.55 20.65 14 11698 1307 29561508
Gallbladder empyema 32.49 20.65 7 11705 56 29562759
Inappropriate antidiuretic hormone secretion 32.43 20.65 30 11682 10902 29551913
Hypoxia 32.16 20.65 63 11649 47316 29515499
Meningeal neoplasm 32.06 20.65 7 11705 60 29562755
Arthralgia 31.92 20.65 8 11704 139609 29423206
Dizziness 31.54 20.65 18 11694 189666 29373149
Leukoencephalopathy 30.85 20.65 19 11693 3748 29559067
Skin toxicity 30.83 20.65 19 11693 3752 29559063
Pseudomonas test positive 30.60 20.65 12 11700 885 29561930
Myocardial infarction 30.18 20.65 4 11708 110292 29452523
Aplasia 29.53 20.65 19 11693 4044 29558771
Clostridium difficile colitis 29.42 20.65 31 11681 13181 29549634
Differentiation syndrome 28.10 20.65 12 11700 1101 29561714
Systemic candida 27.93 20.65 16 11696 2764 29560051
Brain sarcoma 27.77 20.65 5 11707 13 29562802
Pain 27.46 20.65 17 11695 171415 29391400
Malaise 26.73 20.65 15 11697 159587 29403228
Hepatic steatosis 26.28 20.65 31 11681 14915 29547900
Stomatitis 25.97 20.65 50 11662 37063 29525752
Thymus hypoplasia 25.70 20.65 7 11705 160 29562655
Lymphoid tissue hypoplasia 25.70 20.65 7 11705 160 29562655
Product use in unapproved indication 25.49 20.65 84 11628 86791 29476024
Non-alcoholic steatohepatitis 24.84 20.65 10 11702 790 29562025
Prothrombin level abnormal 24.66 20.65 6 11706 86 29562729
Thrombocytopenia 24.51 20.65 112 11600 134711 29428104
Hip deformity 24.05 20.65 6 11706 96 29562719
Myocardial oedema 23.89 20.65 7 11705 210 29562605
Nervous system disorder 23.47 20.65 27 11685 12647 29550168
Vascular access complication 23.46 20.65 7 11705 224 29562591
Disseminated aspergillosis 23.14 20.65 8 11704 413 29562402
Drug resistance 22.97 20.65 35 11677 21505 29541310
Enamel anomaly 22.84 20.65 6 11706 119 29562696
Cerebellar tumour 22.78 20.65 5 11707 44 29562771
Renal replacement therapy 22.68 20.65 5 11707 45 29562770
Leukopenia 22.50 20.65 60 11652 55143 29507672
Superior sagittal sinus thrombosis 22.46 20.65 7 11705 260 29562555
Intracranial pressure increased 22.18 20.65 15 11697 3470 29559345
Infection reactivation 21.89 20.65 10 11702 1077 29561738
Coagulopathy 21.84 20.65 31 11681 17876 29544939
Rash 21.67 20.65 26 11686 189793 29373022
Overdose 21.58 20.65 3 11709 79816 29482999
Intracranial tumour haemorrhage 21.54 20.65 7 11705 298 29562517
Weight decreased 21.47 20.65 17 11695 150888 29411927
Enterococcal infection 21.32 20.65 21 11691 8247 29554568
Recurrent cancer 21.23 20.65 10 11702 1155 29561660
Second primary malignancy 21.06 20.65 19 11693 6686 29556129
Asthenia 21.04 20.65 33 11679 215217 29347598
Hypoalbuminaemia 20.87 20.65 23 11689 10282 29552533

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Febrile neutropenia 1074.13 20.08 701 20503 186956 64290572
Hypofibrinogenaemia 379.26 20.08 93 21111 1685 64475843
Posterior reversible encephalopathy syndrome 330.70 20.08 158 21046 22788 64454740
Aspergillus infection 289.67 20.08 130 21074 16249 64461279
Secondary immunodeficiency 289.45 20.08 82 21122 2642 64474886
Neutropenia 263.09 20.08 357 20847 239267 64238261
Bone marrow failure 262.60 20.08 175 21029 47777 64429751
Sepsis 260.22 20.08 348 20856 229993 64247535
Bronchopulmonary aspergillosis 240.71 20.08 120 21084 18965 64458563
Septic shock 212.80 20.08 215 20989 105222 64372306
Bacterial infection 207.78 20.08 119 21085 24831 64452697
Haematotoxicity 201.72 20.08 94 21110 12802 64464726
Hyperbilirubinaemia 181.56 20.08 103 21101 21102 64456426
Mycobacterium chelonae infection 172.59 20.08 52 21152 2085 64475443
Clostridium difficile colitis 167.67 20.08 107 21097 27116 64450412
Mucormycosis 164.88 20.08 69 21135 7272 64470256
Colitis 145.33 20.08 134 21070 58540 64418988
Pseudomonal sepsis 144.97 20.08 57 21147 5115 64472413
Acute myeloid leukaemia recurrent 139.09 20.08 47 21157 2737 64474791
Parainfluenzae virus infection 128.49 20.08 51 21153 4692 64472836
Neutropenic colitis 126.69 20.08 50 21154 4531 64472997
Multiple-drug resistance 125.83 20.08 55 21149 6447 64471081
Febrile bone marrow aplasia 125.08 20.08 65 21139 11190 64466338
Human herpesvirus 6 infection 118.99 20.08 48 21156 4606 64472922
Pancytopenia 114.24 20.08 184 21020 143125 64334403
Pneumonia fungal 112.43 20.08 56 21148 8821 64468707
Human bocavirus infection 112.35 20.08 28 21176 543 64476985
Hypertriglyceridaemia 111.19 20.08 60 21144 11145 64466383
Acute lymphocytic leukaemia recurrent 104.57 20.08 42 21162 3984 64473544
Pyrexia 101.72 20.08 407 20797 558237 63919291
Venoocclusive disease 101.53 20.08 41 21163 3944 64473584
Second primary malignancy 100.42 20.08 58 21146 12279 64465249
Multiple organ dysfunction syndrome 100.31 20.08 144 21060 101269 64376259
Leukaemia recurrent 99.62 20.08 36 21168 2558 64474970
Fatigue 99.47 20.08 62 21142 748668 63728860
Fungal infection 98.21 20.08 85 21119 34166 64443362
Thymus hypoplasia 94.26 20.08 24 21180 509 64477019
Pain 93.15 20.08 33 21171 553478 63924050
Arthralgia 92.30 20.08 17 21187 442243 64035285
Disseminated intravascular coagulation 92.18 20.08 80 21124 32268 64445260
Bacteraemia 92.12 20.08 74 21130 26837 64450691
Pneumatosis intestinalis 90.80 20.08 41 21163 5188 64472340
Tumour lysis syndrome 89.93 20.08 64 21140 19376 64458152
Mucosal inflammation 86.88 20.08 105 21099 62479 64415049
Thrombocytopenia 85.32 20.08 211 20993 223590 64253938
Cerebral venous sinus thrombosis 83.62 20.08 29 21175 1826 64475702
Neoplasm recurrence 83.47 20.08 35 21169 3704 64473824
Aplasia 82.58 20.08 42 21162 6911 64470617
Lymphoid tissue hypoplasia 81.41 20.08 21 21183 470 64477058
Cytomegalovirus viraemia 77.89 20.08 47 21157 10781 64466747
Glioma 74.67 20.08 20 21184 520 64477008
Abscess bacterial 72.29 20.08 21 21183 740 64476788
Haemophagocytic lymphohistiocytosis 70.20 20.08 53 21151 17556 64459972
Hepatotoxicity 68.88 20.08 75 21129 39887 64437641
Diffuse alveolar damage 67.95 20.08 29 21175 3206 64474322
Malaise 67.66 20.08 23 21181 396224 64081304
Enterobacter infection 67.43 20.08 30 21174 3666 64473862
Blood culture positive 66.73 20.08 38 21166 7830 64469698
Viral infection 66.11 20.08 70 21134 36070 64441458
Enteritis 65.84 20.08 44 21160 12033 64465495
Cardiotoxicity 64.76 20.08 41 21163 10233 64467295
Respiratory failure 63.53 20.08 154 21050 161029 64316499
Oesophageal candidiasis 63.41 20.08 37 21167 7980 64469548
Ejection fraction decreased 62.34 20.08 61 21143 28646 64448882
Cerebral venous thrombosis 61.79 20.08 25 21179 2416 64475112
Myelosuppression 60.07 20.08 55 21149 23775 64453753
Dizziness 56.43 20.08 36 21168 430127 64047401
Cytomegalovirus chorioretinitis 56.39 20.08 29 21175 4883 64472645
Coronavirus infection 55.94 20.08 30 21174 5500 64472028
Glioblastoma multiforme 55.91 20.08 19 21185 1125 64476403
Rhinovirus infection 55.64 20.08 31 21173 6125 64471403
Cystitis bacterial 55.36 20.08 15 21189 408 64477120
Differentiation syndrome 55.33 20.08 22 21182 2032 64475496
Blood fibrinogen decreased 55.11 20.08 20 21184 1438 64476090
Blood bilirubin increased 54.35 20.08 80 21124 57473 64420055
Device related infection 53.68 20.08 58 21146 30568 64446960
Left atrial hypertrophy 52.31 20.08 10 21194 50 64477478
Acute myeloid leukaemia 51.66 20.08 54 21150 27409 64450119
Drug hypersensitivity 49.84 20.08 9 21195 237806 64239722
Pseudomonas test positive 49.82 20.08 19 21185 1569 64475959
Norovirus test positive 49.82 20.08 14 21190 437 64477091
Enterococcal infection 49.30 20.08 39 21165 13827 64463701
Viraemia 49.15 20.08 21 21183 2328 64475200
Candida infection 49.04 20.08 56 21148 31363 64446165
Osteonecrosis 48.67 20.08 53 21151 28176 64449352
Staphylococcal sepsis 47.42 20.08 37 21167 12862 64464666
Dyspnoea 46.52 20.08 105 21099 718569 63758959
Fusarium infection 46.47 20.08 18 21186 1551 64475977
Minimal residual disease 46.32 20.08 13 21191 404 64477124
Inappropriate antidiuretic hormone secretion 45.87 20.08 46 21158 22243 64455285
Fall 45.58 20.08 42 21162 416784 64060744
Lower respiratory tract infection fungal 44.94 20.08 15 21189 840 64476688
Hypoxia 44.52 20.08 93 21111 88056 64389472
Leukopenia 44.51 20.08 101 21103 101141 64376387
Disseminated aspergillosis 44.39 20.08 14 21190 654 64476874
Ileus paralytic 44.29 20.08 30 21174 8385 64469143
Nausea 43.01 20.08 125 21079 785675 63691853
Renal replacement therapy 42.85 20.08 10 21194 145 64477383
Systemic mycosis 42.84 20.08 19 21185 2304 64475224
Respiratory distress 42.72 20.08 68 21136 52263 64425265
Carotid intima-media thickness increased 42.20 20.08 9 21195 84 64477444
Pruritus 41.12 20.08 26 21178 312374 64165154
Geotrichum infection 40.03 20.08 14 21190 904 64476624
Angiokeratoma 39.14 20.08 10 21194 215 64477313
Weight decreased 38.69 20.08 23 21181 285716 64191812
Depression 38.26 20.08 7 21197 183284 64294244
Herpes simplex 38.25 20.08 30 21174 10506 64467022
Pneumonia moraxella 38.07 20.08 8 21196 69 64477459
Stenotrophomonas infection 37.73 20.08 19 21185 3061 64474467
Ankle brachial index decreased 37.67 20.08 8 21196 73 64477455
Encephalitis 37.65 20.08 32 21172 12539 64464989
Large intestine infection 37.53 20.08 18 21186 2610 64474918
Pulse waveform abnormal 37.48 20.08 8 21196 75 64477453
Electrocardiogram PR shortened 37.26 20.08 10 21194 262 64477266
Central nervous system fungal infection 37.25 20.08 11 21193 411 64477117
Acute monocytic leukaemia 36.72 20.08 11 21193 432 64477096
Oesophageal stenosis 36.55 20.08 20 21184 3814 64473714
Pulmonary haemorrhage 36.48 20.08 32 21172 13077 64464451
Neurotoxicity 36.42 20.08 45 21159 27359 64450169
Abdominal discomfort 35.89 20.08 8 21196 182314 64295214
Peripheral swelling 35.89 20.08 12 21192 209141 64268387
Bacterial sepsis 35.52 20.08 25 21179 7432 64470096
Systemic candida 35.43 20.08 22 21182 5307 64472221
Acute respiratory distress syndrome 35.14 20.08 53 21151 38882 64438646
Pseudomonas infection 35.14 20.08 36 21168 17847 64459681
Infusion related reaction 34.93 20.08 6 21198 164461 64313067
Leukoencephalopathy 34.69 20.08 24 21180 6943 64470585
Insomnia 34.56 20.08 11 21193 197825 64279703
Myocardial infarction 33.20 20.08 7 21197 165814 64311714
Venoocclusive liver disease 33.12 20.08 27 21177 9988 64467540
Product use in unapproved indication 32.97 20.08 130 21074 176488 64301040
Escherichia infection 32.49 20.08 32 21172 15136 64462392
Antithrombin III decreased 32.49 20.08 10 21194 431 64477097
Intracranial pressure increased 32.29 20.08 23 21181 6966 64470562
Neutropenic sepsis 32.20 20.08 39 21165 23233 64454295
Urticaria 32.12 20.08 5 21199 147312 64330216
Candida endophthalmitis 32.10 20.08 8 21196 155 64477373
Pleural effusion 32.06 20.08 103 21101 126456 64351072
Hepatic steatosis 32.04 20.08 45 21159 30962 64446566
Venous thrombosis 31.81 20.08 22 21182 6359 64471169
Superior sagittal sinus thrombosis 31.78 20.08 12 21192 964 64476564
Alanine aminotransferase increased 31.53 20.08 109 21095 138922 64338606
Overdose 31.41 20.08 7 21197 159559 64317969
Skin toxicity 31.13 20.08 22 21182 6580 64470948
Gastroenteritis norovirus 30.75 20.08 16 21188 2759 64474769
Gallbladder empyema 30.63 20.08 7 21197 92 64477436
Muscle spasms 30.27 20.08 5 21199 141018 64336510
Blast crisis in myelogenous leukaemia 30.21 20.08 11 21193 798 64476730
Pulmonary mucormycosis 30.17 20.08 11 21193 801 64476727
Pancreatitis acute 30.03 20.08 52 21152 42803 64434725
Left ventricular dysfunction 29.52 20.08 32 21172 16922 64460606
Tachycardia 29.46 20.08 112 21092 149467 64328061
Aborted pregnancy 29.42 20.08 6 21198 44 64477484
Hypersensitivity 29.24 20.08 14 21190 196438 64281090
Intussusception 28.92 20.08 11 21193 902 64476626
Brain sarcoma 28.70 20.08 5 21199 13 64477515
Swelling 27.82 20.08 9 21195 160209 64317319
Bone marrow disorder 27.66 20.08 15 21189 2810 64474718
Chronic myeloid leukaemia recurrent 27.65 20.08 8 21196 278 64477250
Personality change due to a general medical condition 27.56 20.08 7 21197 147 64477381
Diarrhoea 27.10 20.08 134 21070 722570 63754958
Hypoalbuminaemia 26.73 20.08 31 21173 17643 64459885
Cytomegalovirus infection reactivation 26.73 20.08 19 21185 5737 64471791
Lung opacity 25.92 20.08 15 21189 3184 64474344
Myalgia 25.67 20.08 10 21194 158607 64318921
Escherichia bacteraemia 25.47 20.08 18 21186 5385 64472143
Myelopathy 25.40 20.08 16 21188 3958 64473570
Neoplasm progression 25.24 20.08 47 21157 40917 64436611
Toxicity to various agents 25.19 20.08 51 21153 363462 64114066
Musculoskeletal stiffness 25.07 20.08 5 21199 123201 64354327
Rash 24.96 20.08 73 21131 458476 64019052
Lymphopenia 24.69 20.08 36 21168 25621 64451907
Blood pressure increased 24.62 20.08 13 21191 172539 64304989
Genotoxicity 24.59 20.08 5 21199 36 64477492
Leukoerythroblastosis 24.09 20.08 7 21197 247 64477281
Coagulopathy 24.04 20.08 40 21164 31880 64445648
Streptococcal bacteraemia 23.84 20.08 14 21190 3053 64474475
Non-alcoholic steatohepatitis 23.79 20.08 12 21192 1940 64475588
Graft versus host disease in skin 23.34 20.08 17 21187 5330 64472198
Escherichia sepsis 23.03 20.08 19 21185 7146 64470382
Fungal sepsis 22.60 20.08 11 21193 1647 64475881
Contusion 22.42 20.08 5 21199 113960 64363568
T-cell type acute leukaemia 22.33 20.08 6 21198 158 64477370
Pain in extremity 22.31 20.08 41 21163 303044 64174484
Escherichia test positive 22.24 20.08 13 21191 2812 64474716
Alpha haemolytic streptococcal infection 22.19 20.08 11 21193 1714 64475814
Back pain 22.05 20.08 30 21174 250141 64227387
Myocardial oedema 21.99 20.08 7 21197 337 64477191
Asthenia 21.96 20.08 70 21134 427974 64049554
Gait disturbance 21.72 20.08 15 21189 172140 64305388
Staphylococcal infection 21.64 20.08 50 21154 50628 64426900
Peripheral motor neuropathy 21.64 20.08 13 21191 2957 64474571
Cerebellar tumour 21.39 20.08 5 21199 73 64477455
Pancreatitis 21.39 20.08 55 21149 59552 64417976
Cerebral ischaemia 21.31 20.08 21 21183 9941 64467587
Hip deformity 21.27 20.08 6 21198 190 64477338
Atypical pneumonia 21.24 20.08 16 21188 5278 64472250
Appendicitis 20.86 20.08 24 21180 13545 64463983
Graft versus host disease 20.51 20.08 24 21180 13789 64463739
Infection reactivation 20.50 20.08 11 21193 2019 64475509
Weight increased 20.45 20.08 24 21180 213324 64264204
Cerebral haemorrhage 20.28 20.08 49 21155 51041 64426487
Ureaplasma infection 20.21 20.08 8 21196 730 64476798
Dehydration 20.13 20.08 25 21179 216738 64260790
Overgrowth fungal 20.11 20.08 5 21199 96 64477432

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L01DB02 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES
Anthracyclines and related substances
ATC L01XY01 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
OTHER ANTINEOPLASTIC AGENTS
Combinations of antineoplastic agents
FDA CS M0028312 Anthracyclines
FDA MoA N0000000176 Topoisomerase Inhibitors
FDA EPC N0000175414 Anthracycline Topoisomerase Inhibitor
MeSH PA D000903 Antibiotics, Antineoplastic
MeSH PA D000970 Antineoplastic Agents
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D059005 Topoisomerase II Inhibitors
CHEBI has role CHEBI:35610 antineoplastic agents

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Acute lymphoid leukemia indication 91857003 DOID:9952
Acute myeloid leukemia, disease indication 91861009
Erythroleukemia, FAB M6 indication 93451002
Kaposi's sarcoma indication 109385007
Acute promyelocytic leukemia, FAB M3 indication 110004001
Acute monocytic/monoblastic leukemia indication 413442004
Blast crisis of chronic myeloidleukemia indication 413656006
Nephroblastoma off-label use 302849000 DOID:2154
Neuroblastoma off-label use 432328008 DOID:769
Mycosis contraindication 3218000 DOID:1564
Pericarditis contraindication 3238004 DOID:1787
Ventricular tachycardia contraindication 25569003
Viral disease contraindication 34014006 DOID:934
Hyperuricemia contraindication 35885006 DOID:1920
Conduction disorder of the heart contraindication 44808001
Chronic heart failure contraindication 48447003
Myocarditis contraindication 50920009 DOID:820
Epilepsy contraindication 84757009 DOID:1826
Cardiomyopathy contraindication 85898001 DOID:0050700
Bacterial infectious disease contraindication 87628006
Kidney disease contraindication 90708001 DOID:557
Disease of liver contraindication 235856003 DOID:409
Pregnancy, function contraindication 289908002
Neutropenic disorder contraindication 303011007 DOID:1227
Bone marrow depression contraindication 307762000
Breastfeeding (mother) contraindication 413712001
Granulocytopenic disorder contraindication 417672002
Protozoal Infection contraindication




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 7.85 acidic
pKa2 9.79 acidic
pKa3 11.6 acidic
pKa4 8.6 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
100MG;44MG VYXEOS CELATOR PHARMS N209401 Aug. 3, 2017 RX POWDER INTRAVENOUS 8431806 April 22, 2025 FOR THE TREATMENT OF NEWLY-DIAGNOSED THERAPY-RELATED ACUTE MYELOID LEUKEMIA (T-AML) OR AML WITH MYELODYSPLASIA-RELATED CHANGES (AML-MRC) IN ADULTS AND PEDIATRIC PATIENTS 1 YEAR AND OLDER
100MG;44MG VYXEOS CELATOR PHARMS N209401 Aug. 3, 2017 RX POWDER INTRAVENOUS 7850990 Jan. 23, 2027 FOR THE TREATMENT OF NEWLY-DIAGNOSED THERAPY-RELATED ACUTE MYELOID LEUKEMIA (T-AML) OR AML WITH MYELODYSPLASIA-RELATED CHANGES (AML-MRC) IN ADULTS AND PEDIATRIC PATIENTS 1 YEAR AND OLDER
100MG;44MG VYXEOS CELATOR PHARMS N209401 Aug. 3, 2017 RX POWDER INTRAVENOUS 8022279 Sept. 14, 2027 FOR THE TREATMENT OF NEWLY-DIAGNOSED THERAPY-RELATED ACUTE MYELOID LEUKEMIA (T-AML) OR AML WITH MYELODYSPLASIA-RELATED CHANGES (AML-MRC) IN ADULTS AND PEDIATRIC PATIENTS 1 YEAR AND OLDER
100MG;44MG VYXEOS CELATOR PHARMS N209401 Aug. 3, 2017 RX POWDER INTRAVENOUS 8092828 April 1, 2029 FOR THE TREATMENT OF NEWLY-DIAGNOSED THERAPY-RELATED ACUTE MYELOID LEUKEMIA (T-AML) OR AML WITH MYELODYSPLASIA-RELATED CHANGES (AML-MRC) IN ADULTS AND PEDIATRIC PATIENTS 1 YEAR AND OLDER
100MG;44MG VYXEOS CELATOR PHARMS N209401 Aug. 3, 2017 RX POWDER INTRAVENOUS 10166184 Oct. 15, 2032 METHOD OF RECONSTITUTING A LYOPHILIZED LIPOSOMAL COMPOSITION FOR ADMINISTERING CYTARABINE AND DAUNORUBICIN TO TREAT NEWLY-DIAGNOSED THERAPY-RELATED AML (T-AML) OR AML WITH MYELODYSPLASIA-RELATED CHANGES (AML-MRC) IN PATIENTS 1 YEAR AND OLDER
100MG;44MG VYXEOS CELATOR PHARMS N209401 Aug. 3, 2017 RX POWDER INTRAVENOUS 10835492 Oct. 15, 2032 METHOD OF ADMINISTERING A RECONSTITUTED LIPOSOMAL COMPOSITION CONTAINING CYTARABINE AND DAUNORUBICIN TO TREAT NEWLY-DIAGNOSED THERAPY-RELATED AML (T-AML) OR AML WITH MYELODYSPLASIA-RELATED CHANGES (AML-MRC) IN PATIENTS 1 YEAR AND OLDER
100MG;44MG VYXEOS CELATOR PHARMS N209401 Aug. 3, 2017 RX POWDER INTRAVENOUS 10028912 Sept. 29, 2034 METHOD OF ADMINISTERING A RECONSTITUTED LIPOSOMAL COMPOSITION CONTAINING CYTARABINE AND DAUNORUBICIN TO TREAT NEWLY-DIAGNOSED THERAPY-RELATED AML (T-AML) OR AML WITH MYELODYSPLASIA-RELATED CHANGES (AML-MRC) IN PATIENTS 1 YEAR AND OLDER
100MG;44MG VYXEOS CELATOR PHARMS N209401 Aug. 3, 2017 RX POWDER INTRAVENOUS 10028912 Sept. 29, 2034 METHOD OF RECONSTITUTING A LYOPHILIZED LIPOSOMAL COMPOSITION FOR ADMINISTERING CYTARABINE AND DAUNORUBICIN TO TREAT NEWLY-DIAGNOSED THERAPY-RELATED AML (T-AML) OR AML WITH MYELODYSPLASIA-RELATED CHANGES (AML-MRC) IN PATIENTS 1 YEAR AND OLDER

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
100MG;44MG VYXEOS CELATOR PHARMS N209401 Aug. 3, 2017 RX POWDER INTRAVENOUS March 30, 2024 NEW PATIENT POPULATION
100MG;44MG VYXEOS CELATOR PHARMS N209401 Aug. 3, 2017 RX POWDER INTRAVENOUS Aug. 3, 2024 TREATMENT OF ADULTS WITH NEWLY DIAGNOSED THERAPY-RELATED ACUTE MYELOID LEUKEMIA (T-AML) OR AML WITH MYELODYSPLASIA-RELATED CHANGES (AML-MRC)
100MG;44MG VYXEOS CELATOR PHARMS N209401 Aug. 3, 2017 RX POWDER INTRAVENOUS March 30, 2028 TREATMENT OF NEWLY-DIAGNOSED THERAPY-RELATED ACUTE MYELOID LEUKEMIA (T-AML) OR AML WITH MYELODYSPLASIA-RELATED CHANGES (AML-MRC) IN PEDIATRIC PATIENTS AGES 1 YEAR AND OLDER

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
DNA topoisomerase 2-alpha Enzyme INHIBITOR WOMBAT-PK CHEMBL
Multidrug resistance-associated protein 1 Transporter WOMBAT-PK
Multidrug resistance protein 1 Transporter WOMBAT-PK
Multidrug resistance-associated protein 6 Transporter WOMBAT-PK
72 kDa type IV collagenase Enzyme IC50 5.72 CHEMBL
ATP-binding cassette sub-family G member 2 Transporter WOMBAT-PK
ORF 73 Unclassified AC50 5.63 CHEMBL

External reference:

IDSource
4019704 VUID
N0000147796 NUI
D01264 KEGG_DRUG
23541-50-6 SECONDARY_CAS_RN
371770-68-2 SECONDARY_CAS_RN
1364321 RXNORM
4018061 VANDF
4019704 VANDF
C0011015 UMLSCUI
CHEBI:41977 CHEBI
DM1 PDB_CHEM_ID
CHEMBL178 ChEMBL_ID
CHEMBL1563 ChEMBL_ID
CHEMBL1200475 ChEMBL_ID
D003630 MESH_DESCRIPTOR_UI
DB00694 DRUGBANK_ID
7063 IUPHAR_LIGAND_ID
2257 INN_ID
ZS7284E0ZP UNII
30323 PUBCHEM_CID
11753 MMSL
4538 MMSL
d00205 MMSL
002662 NDDF
004821 NDDF
108790000 SNOMEDCT_US
35300007 SNOMEDCT_US
372715008 SNOMEDCT_US
65972004 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Daunorubicin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0143-9550 INJECTION 5 mg INTRAVENOUS NDA 21 sections
Daunorubicin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0143-9551 INJECTION 5 mg INTRAVENOUS NDA 21 sections
daunorubicin hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0703-5233 INJECTION, SOLUTION 5 mg INTRAVENOUS ANDA 26 sections
Daunorubicin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 42658-019 INJECTION, SOLUTION 5 mg INTRAVENOUS ANDA 22 sections
Daunorubicin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 42658-021 INJECTION, SOLUTION 5 mg INTRAVENOUS ANDA 22 sections
VYXEOS HUMAN PRESCRIPTION DRUG LABEL 2 68727-745 INJECTION, POWDER, LYOPHILIZED, FOR SUSPENSION 44 mg INTRAVENOUS NDA 28 sections